ישראל - עברית - Ministry of Health

medison pharma ltd - carglumic acid - טבליות ניתנות לפיזור - carglumic acid 200 mg - carglumic acid

ישראל - עברית - Ministry of Health

beammed ltd. - מומחה - מכשיר לטיפול בצלוליטיס והצרת היקפים

ישראל - עברית - Ministry of Health

סינרון ביוטי בע"מ - כלל האוכלוסיה - מיועד להלבנת שיניים

ישראל - עברית - Ministry of Health

beammed ltd. - רופא - מיכשור לטיפולים אסתטיים המבוסס על לייזר ו-fr

ישראל - עברית - Ministry of Health

taro international ltd - bicalutamide 150 mg - film coated tablets - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0) bicamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

ישראל - עברית - Ministry of Health

inovamed ltd - bicalutamide - טבליות מצופות פילם - bicalutamide 50 mg - bicalutamide - bicalutamide - for the treatment of advanced prostate cancer in combination with luteinising hormone-releasing hormone (lhrh) analog therapy or surgical castration.

ישראל - עברית - Ministry of Health

inovamed ltd - anastrozole - טבליות מצופות פילם - anastrozole 1 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

ישראל - עברית - Ministry of Health

taro international ltd - anastrozole 1 mg - tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

ישראל - עברית - Ministry of Health

inovamed ltd - letrozole 2.5 mg - film coated tablets - letrozole - for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined locally advanced or metastatic breast cancer. for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy.adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

ישראל - עברית - Ministry of Health

inovamed ltd - exemestane 25 mg - film coated tablets - exemestane - exemestane inovamed is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane inovamed is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. exemestane inovamed is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.